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To evaluate the anti-hepatitis activity of non-pharmacopoeial compound formulation on CCl4 induces hepatotoxicity in 
albino rats.CCl4 is used to produce hepatic damage in albino rats in the dose of 2 mL/kg BW, i.p. for 6 days. The anti-
hepatitis effect of low dose (70 mg/100 g), high dose (140 mg/100 g) and 50% ethanolic extract (15 mg/100 g) of non-
pharmacopoeial compound formulation (Majoon) was assessed in CCl4 (2 mL/kg BW i.p.) induce hepatic damage in albino 
rats. The biochemical parameters such as SGOT (AST), SGPT (ALT), ALP, total bilirubin and total protein were estimated 
and the antioxidant activity was also estimated. These biochemical observations were supplemented by histopathological 
study of liver sections. Silymarin (10 mg/100 g B.W.p.o.) was used as a standard hepatoprotective drug for positive control. 
Data was analysed by one way ANOVA test. Administration of non-pharmacopoeial compound formulation and its extract 
significantly prevented CCl4 induced elevation of serum ALT, AST, ALP, total billirubin and total protein level. The 
histopathological study revealed hepatocytes regeneration. The test drug also decreases lipid peroxidaion. So, the test drug 
was found effective as anti-hepatitis and antioxidant effect. The result was comparable to that of Silymarin. The results of 
present study show that the compound formulation has significant anti-hepatitis activity. 
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Liver is the most important organ of metabolism and 
excretion1. Liver is a key organ in coordinating the 
homeostasis of the body2. Alteration in normal 
physiological roles may lead to impaired liver 
function3. According to the WHO data published in 
May 2014, liver disease deaths in India reached 
2,16,865 or 2.44% of total deaths. Hepatocellular 
carcinoma is one of the ten most common tumors in 
the world with over 2,50,000 new cases per year1. 
Hepatitis is the commonest liver disorder which 
prevails throughout the world. Modern medicine 
offers little by way of cure, but, so far, there is no 
effective treatment available for hepatitis and to stop 
the progression of Cirrhosis in patients with liver 
disease4. Herbs are known to play a major role in the 
management of various liver diseases. Liver 
protective drugs contain a variety of chemicals 
constituents in which flavonoids and volatile oils are 
the most commonly encountered livoprotective active 
constituents1. In Ayurveda about 77 and in Tibb-e-
Unani about 42 herbal drugs are used as 
hepatoprotective agents. Nearly 160 phyto-
constituents obtained from 101 plants belonging to 52 
families have been reported to have antihepatotoxic 
activity1. In India more than 87 medicinal plants are 
used in different combinations for this purpose5. 
Researchers explore the potential in the traditional 
medicine (Unani medicine) as it possesses number of 
safe curative agents for liver disorders. The present 
study was conducted on a non-Pharmacopoeial 
compound formulation (NPCF). This is a new 
formulation based on ten ingredients viz. Rose petals 
(Rosa damascene Mill.), Rubarb root (Rheum emodii 
Wall.), Cassia bark (Cinnamomum cassia Blume.), 
Jatamansi root (Nardostachys jatamansi DC.), Kasni 
seeds (Cichorium intybus L.), Punarnawa root 
(Boerhavia diffusa L.), Asaroon root (Asarum 
europoeum L.), Orris root (Iris ensata Thunb.), 
Saffron (Crocus sativus L.) and Lac resin (Laccifer 
lacca Kerr.) (Table 1). They are hepatoprotective, 
tonic, anti-inflammatory, diuretic, deobsturent and 
antioxidant in property6-10. This formulation was a 
semi-solid paste called as ‘Majoon’ in Unani 
Medicine. The Majoon and its hydroalcoholic extract 
from Soxhlet apparatus were used for the study in 
albino rats. 
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Materials and Methods 
 
Chemicals 
Silymarin was purchased from Sigma-Aldrich, 
Germany. Carbon tetrachloride (CCl4) was purchased 
from Ranbaxy lab. Ltd. India. ALT, AST, ALP, 
Serum bilirubin, Total protein kits were purchased 
from Siemens pvt. Ltd. 
 
Collection of material 
Majoon’s ingredients were procured from 
Dwakhana Tibbiya College, AMU, Aligarh and were 
identified and authenticated in the Pharmacognosy 
section of Department of Ilmul Advia, Faculty of 
Unani Medicine, AMU Aligarh, followed by 
preparation of Majoon. 
 
Preparation and Administration 
The Majoon (NPCF) was prepared according to the 
standard method described in Unani Formulary11 and 
Pharmacopoeia. Before preparation of majoon the 
single plant drugs of formulation were dried in oven 
at different temperatures such as roots and barks at 50 
– 60°C, flowers and seeds at 20–30°C12. After that the 
drugs were cleaned and crushed to make fine powder 
in electric grinder at 80 meshes sieves except Luk and 
Zafran.  
The whole majoon in low and high dose was 
administered per orally as per route of choice of Unani 
Medicine. The 50% ethanolic extract was prepared by 
Soxhlet’s apparatus13. All forms of test drug were 
dissolved in distilled water and administered orally by 
a feeding canula after shaking the solution well. The 
doses of the test drug for the study were calculated by 
multiplying the clinical doses with appropriate 
conversion factor of 7 for rats14. 
The clinical dose of Majoon: 5-10 g. 
 
Animals 
Acute study was conducted for NPCF (Test drug) 
on 36 Albino rats of Wistar strain of either sex, 
weighing 150-200 g which were divided into 6 groups 
of 6 animals each. The animals were kept under 
standard laboratory conditions of 12 h light and dark 
period. Standard rat diet and water were given ad 
libitum. The study protocol was approved by the 
institutional animal ethics committee. 
 
Experimental design 
The animals were deprived of food for 12 h before 
the treatment. Test drugs were administered to the 
animals by oral feeding canula for 6 days. Carbon 
tetrachloride (CCl4), a hepatotoxic agent, was injected 
in the form of suspension to the animals 
intraperitoneally in a dose of 2 mL/kg B.W. on the 6th 
day except group I (Plain Control). On the seventh 
day all the animals were sacrificed by ether 
anaesthesia. 
 
The animals groups were treated as follow 
 
Group I: Served as normal control and 
administered distilled water orally for 7 
days. 
Group II: Served as Negative control, CCl4 was 
given as 1:1 in Olive oil in the dose of 0.2 
mL/100g B.W. i.p. on 6th day.  
Group III: Served as Standard control, Silymarin was 
given in the dose of 10mg/100 g B.W. 
orally + CCl4 (0.2 mL/100g) on 6th day. 
Group IV: Low dose of NPCF (70mg/100g B.W.) 
orally + CCl4 on 6thday. 
Group V: High dose of NPCF (140mg/100g B.W.) 
orally + CCl4 on 6thday.  
Group VI: 50% Alcoholic extract of NPCF 
(15mg/100g B.W.) orally+ CCl4 on 
6thday. 
 
Collection of biological samples 
After sacrificing the animals, the blood was 
collected in serum separating tubes (gel and clot 
Table 1 — List of ingredients of Majoon 
S No Unani name Amount Botanical name Family Parts used 
1. Gul-e-surkh 30g Rosa damascene Mill. Rosaceae Flower 
2. Rewandchini 10g Rheum emodi Wall. Polygonaceae Rhizome 
3. TajQalmi 10g Cinnamomum cassia Blume. Lauraceae Bark 
4. Balchad 10g NardostachysjatamansiDC. Valerianaceae Root 
5. Kasni 10g Cichoriumintybus L. Asteraceae Seed 
6. Punarnawa 10g Boerhaviadiffusa L. Nyctaginaceae Root 
7. Asaroon 10g Asarumeuropoeum L. Aristolochiaceae Root 
8. Irsa 10g Iris ensataThunb. Iridaceae Root 
9. Zafran 3g Crocus sativus L. Iridaceae Stigma,Style 
10. Luk-e-Maghsool 10g From an insect, Lacciferlacca Kerr. Lacciferidae Resinous secretion 
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activator) and centrifuged at 7000 rpm for 15 min and 
stored at 2-4°C. The liver was also taken immediately 
and fixed in 10% formalin. Biochemical markers and 
protein were estimated in serum. 
 
Estimation of biological parameters 
The protective effect of the test and standard drugs 
was studied by estimating the concentration of 
biochemical markers of liver function, viz. serum 
bilirubin, serum alanine transaminase (ALT/SGPT), 
serum aspartate transaminase (AST/SGOT), serum 
alkaline phosphatase (SALP) and serum total protein 
(STP). 
 
Histopathological study 
For histological study, the sections of liver were 
removed and fixed in 10% formaline. The fixation 
was done immediately to check autolysis, to preserve 
as nearly as possible the natural state of the tissue 
cells. Care was taken to maintain the correct volume 
of the fixative15. The tissue was processed and 
sections were cut. The slides were prepared and 
stained with haematoxyline and eosin stain and 
studied for histopathological changes by light 
microscopy under various magnifications.  
 
Statistical analysis 
The concentrations of each parameter in various 
animal groups were statistically compared for 
determining significance of difference by one-way 
ANOVA Test followed by Tukey: Compare all pairs 
of column. The analysis was carried out by using In 
Stat Graph Pad software. Values were expressed as 
Mean±SEM. A probability (P) values of less than 
0.05 were considered as statistically significant. 
Results 
The effect of the test drug on serum marker enzymes 
is presented in Table 2. The level of serum bilirubin, 
ALT, AST, ALP were significantly increased while total 
protein was found to be significantly decreased 
(p<0.001) in CCl4 treated rats as compare to plain 
control group, indicating liver damage Fig. 1. Silymarin 
was found to significantly decrease (p<0.001) the 
biochemical parameters of liver function as compared to 
the group II, and serum total protein was increased 
significantly (p<0.01). It confirms that the Silymarin 
possesses potent hepatoprotective activity. In 
comparison of low dose, high dose and hydroalcoholic 
extract of the test drug, it was observed that the 
decrement produce by the high dose (140 mg/100g) and 
Table 2 — Effect of test drug (NPCF) and standard drug on biochemical parameters of liver function in CCl4induced hepatotoxicity 
Groups S. ALT / SGPT  
(Unit/L) Mean±SE 
S. AST / SGOT  
(Unit/L) Mean±SE 
Serum Bilirubin 
(mg/dl) Mean±SE 
S. Alkaline Phosphatase  
(U/L) Mean±SE 
Total Protein  
(g/dl) Mean±SE 
Plain control 
(Distilled water) 
30.618±2.44 37.39±1.49 0.694±0.219 61.064±3.33 6.756±0.279 
Hepatotoxic CCl4 
0.2mL/100g 
90.762±3.594 x3 93.5±2.00 x3 2.568±0.155 x3 178.34±2.832  x3 4.57±0.252 x3 
Standard (Silymarin) 
10mg/100g 
38.74±2.52 y3 51.73±2.64 x3 y3 0.584±0.114 y3 93.074±2.11 x3 y3 6.385±0.329 y2 
Low dose 
(70mg/100g) 
64.31±3.179 x3 y3 z3 72.61±2.74 x3 y3 z3 1.866±0.105 x3 y1 z3 163.818±2.062 x3 y1 z3 5.318±0.129 x2 z1 
High dose 
(140mg/100g) 
62.019±0.900 x3 y3 z3 63.63±0.98 x3 y3 z2 a1 0.822±0.157 y3 a3 131.856±3.804 x3 y3 z3 a3 6.131±0.249 y2 
50%Alcoholic extract 
(15mg/100g) 
40.86±2.901 y3 a3 b3 62.78±1.51 x3 y3 z2 a1 1.022±0.174 y3 a1 122.03±3.82 x3 y3 z3 a3 6.108±0.144 y2 
N=6, x = Against Plain control, y = Against CCl4, z = Against Standard, a = Against Low dose, b = Against High dose, c = 50%Aloholic 
extract, 1 = p< 0.05, 2 = p< 0.01, 3 = p< 0.001  
 
Fig. 1 — Graphs showing effect of CCl4,Silymarin and Test drugs 
on (a) ALT, (b) AST, (c) Bilirubin, (d) ALP, (e) Total Protein 
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the hydroalcoholic extract (15 mg/100g) in biochemical 
and metabolic parameters of liver function was greater 
than the low dose (70 mg/10g). It showed that the effect 
of high dose and hydroalcoholic extract of the formulation 
are on the whole equivalent to the effect of Silymarin, 
because Silymarin, high dose and extract significantly 
reduced (p<0.001) the serum ALT [Fig. 1(a)], AST [Fig. 
1(b)], bilirubin [Fig. 1(c)] and ALP[Fig. 1(d)]. The high 
dose produced slightly greater reduction (p<0.001) in 
serum bilirubin [Fig. 1(c)] and ALP [Fig. 1(d)] than low 
dose. The hydroalcoholic extract of the test drug produced 
greater reduction in serum ALT [Fig. 1(a)] and ALP [Fig. 
1(d)] (p<0.001) than low dose. Administration of test drug 
as a whole in single and double dose or its hydroalcoholic 
extract remarkably prevented CCl4 induced hepatotoxicity 
in rats by significantly decreasing serum bilirubin, ALT, 
AST, ALP and by increasing total protein [Fig. 1(e)] and 
(Table 2). 
Histopathological studies of the liver sections of 
control and experimental animals shown in Fig. 2 were 
carried out to test the hepatoprotective and anti-hepatitis 
effect of the test drug. 
The Fig. 2(a) shows the liver section of Group I 
(Normal control) animals, which has normal 
architecture, where the central vein, portal tracts, 
hepatocytes and sinusoids appear normal. Fig. 2(b) 
(Group II) shows hepatocellular damage, there was 
hepatocyte necrosis, degeneration, presence of fatty 
vacuoles, infiltration of inflammatory cells. Fig. 2C 
(Group III) shows regeneration of hepatocytes, no fatty 
degeneration, absence of fatty vacuoles. Fig. 2D & 2E 
(Group IV & V) shows significant liver protection 
against toxicant as evident by the presence of normal 
hepatocytes, absence of necrosis and less fatty 
infiltration. Fig. 2(f) (Group VI) shows regeneration of 
hepatocytes and their arrangement around central vein 
with mild fatty changes. Hepatic architecture was 
similar to that of control. The histopathological 
observation showed that the test drug has an ability to 
initiate regeneration of hepatocytes. All the results 
showed that the drug improves the functional and 
structural status of liver following the exposure to 
known liver toxicant, CCl4. 
 
 
Discussion 
This study was under taken to demonstrate the 
hepatoprotective ability and anti-hepatitis activity of 
non pharmacopoeial compound formulation (Majoon) 
on liver damage induced by CCl4. Biochemical markers 
of liver function and histopathological features were 
taken as the indicators of liver toxicity or 
hepatoprotection in light of their deviation from normal 
values or their proximity with the normal. Estimating 
the activities of serum marker enzymes like ALT and 
AST can make assessment of liver function. When 
hepatocytes plasma membrane is damaged, various 
enzymes normally present in the cytosol are released 
into the blood stream. Their estimations in the serum 
are a useful quantitative marker of the extent and type 
of hepatocellular damage16. Histopathological studies 
give the supportive evidence for the biochemical 
analysis17. In this study, the use of low (single) dose, 
high (double) dose and hydroalcoholic extract of the 
test drug protects liver from damage by CCl4 as evident 
by improved histological picture and biochemical 
markers of hepatic damage. This formulation exerted 
its hepatoprotective and anti-hepatitis effect might be 
by inhibiting lipid peroxidation mediated by CCl4 due 
to its anti-oxidant activity. The presence of flavonoids, 
tannins, phenols, terpens and sterols in this formulation 
explain its role in hepatoprotection by inhibiting the 
free radicals mediated damage18, claimed that 
flavonoids, terpens and tannins were antioxidant agents 
and may interfere with free radical formation19. 
 
Conclusion 
In the view of above discussion, it was concluded 
that the test drug, viz. Non-pharmacopoeial compound 
 
 
Fig. 2 — Liver histopathology of A-normal control group, B-CCl4
treated group, C-Silymarintreated group, D-Low dosetreated group,
E-High dosetreated group, F-Hydroalcoholictreated group 
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formulation and its hydroalcoholic extract possess 
significant hepatoprotective and anti-hepatitis effect 
against acute hepatic damage induced by CCl4. The 
effect of high dose and hydroalcoholic extract were 
more marked, which was almost equivalent to the effect 
of Silymarin. The test drug (NPCF) produced dose 
dependent response as low and high doses possessing 
significant hepatoprotective effect, but high dose is 
slightly better. The test drug also showed hepatocytes 
regeneration. So, it may be effective in hepatitis and 
chronic liver disease. 
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